Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 2/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 1/20 | 1.00 |
| ▸ | BCL2L2 | Q92843 | 7/20 | 0.73 |
| ▸ | BAD | Q92934 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264548 | 1.00 | BCL2 (1.00) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL158040 | 1.00 | BCL2 (1.00) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13812532 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13982547 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL5970105 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL5970104 | 0.89 | BCL2 (0.80) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL14163443 | 0.88 | KMT2A (0.78) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL13657863 | 0.87 | BCL2 (0.77) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL3426372 | 0.87 | BCL2 (0.76) | BCL2MEN1KMT2AMCL1BCL2L1 | |
| SCHEMBL3426376 | 0.87 | BCL2 (0.76) | BCL2MEN1KMT2AMCL1BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4486761-A1 | MODIFICATION OF BRASSINOSTEROID RECEPTOR GENES TO IMPROVE YIELD TRAITS | Pairwise Plants Services, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-119072487-A | Modification of brassinosteroid receptor gene for improving yield traits | 成对植物服务股份有限公司 | 2024-12-03 | — | — | CN | claimed |
| US-20240327858-A1 | MODIFICATION OF BRASSINOSTEROID RECEPTOR GENES TO IMPROVE YIELD TRAITS | PAIRWISE PLANTS SERVICES, INC. | 2024-10-03 | — | — | US | claimed |
| WO-2023168217-A1 | MODIFICATION OF BRASSINOSTEROID RECEPTOR GENES TO IMPROVE YIELD TRAITS | PAIRWISE PLANTS SERVICES, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| US-9426992-B1 | Method for inhibiting conidial germination and mycelial growth of fungi symbiotically associated with bark beetles | Montana State University—Billings (US) | 2016-08-30 | — | — | US | claimed |
| US-RE43615-E1 | Method for controlling the yeast-to-filamentous growth transition in fungi | Montana State University—Billings (US) | 2012-08-28 | — | — | US | claimed |
| US-7825143-B2 | contacting a fungal cell with an anti-fungal small molecule in an amount effective to reduce or inhibit the yeast-to-filamentous growth transition, wherein the anti-fungal small molecule is 5-(p-bromobenzylidine)- alpha -isopropyl-4-oxo-2-thioxo-3-thiozolidineacetic acid | MONTANA STATE UNIVERSITY - BILLINGS (US) | 2010-11-02 | — | — | US | claimed |
| US-20090018173-A1 | Method for controlling the yeast-to-filamentous growth transition in fungi | MONTANA STATE UNIVERSITY - BILLINGS (US) | 2009-01-15 | — | — | US | claimed |
| US-20260027162-A1 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025262113-A1 | COMBINATION THERAPY USING MALT1 AND BCL-2 INHIBITORS AND METHODS OF REDUCING REGULATORY T CELLS | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-26 | — | — | WO | disclosed |
| US-20250270536-A1 | BACTERIAL COMPOSITIONS AND METHODS FOR GROWING BACTERIA ON PARTICLES | MYBIOTICS PHARMA LTD. (IL) | 2025-08-28 | — | — | US | disclosed |
| EP-4555326-A2 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | President And Fellows Of Harvard College (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-119894525-A | Mucispirillum compositions and methods of treating cancer | 哈佛大学校长及研究员协会 | 2025-04-25 | — | — | CN | disclosed |
| EP-4514368-A1 | BACTERIAL COMPOSITIONS AND METHODS FOR GROWING BACTERIA ON PARTICLES | Mybiotics Pharma Ltd (IL) | 2025-03-05 | — | — | EP | disclosed |
| US-7825143-B2 | contacting a fungal cell with an anti-fungal small molecule in an amount effective to reduce or inhibit the yeast-to-filamentous growth transition, wherein the anti-fungal small molecule is 5-(p-bromobenzylidine)- alpha -isopropyl-4-oxo-2-thioxo-3-thiozolidineacetic acid | MONTANA STATE UNIVERSITY - BILLINGS (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | disclosed |
| US-20090018173-A1 | Method for controlling the yeast-to-filamentous growth transition in fungi | MONTANA STATE UNIVERSITY - BILLINGS (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090018173-A1 | Method for controlling the yeast-to-filamentous growth transition in fungi | MONTANA STATE UNIVERSITY - BILLINGS (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2008157003-A2 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | THE BURNHAM INSTITUTE (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027162-A1 | MUCISPIRILLUM COMPOSITIONS AND CANCER TREATMENT METHODS THEREOF | SAAL1, CD74, MUC1 | BCL2 3415/4885MEN1 301/4885KMT2A 3742/4885 |
| US-20090018173-A1 | Method for controlling the yeast-to-filamentous growth transition in fungi | ERG28, MANBA, TALDO1 | BCL2 4182/4885MEN1 2818/4885KMT2A 2469/4885 |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | BCL2 6/4885MEN1 2843/4885KMT2A 2267/4885 |
| US-20090069324-A1 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS | TMBIM6, BCL2L1, BCL2L11 | BCL2 15/4885MEN1 1821/4885KMT2A 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.